Ambien
(Zolpidem Tartrate)Phase 3Small molecule
SanofiZolpidem is used to help people fall asleep at the beginning of the night. It works by slowing down brain activity to allow for sleep and is typically prescribed for short-term use.[1] Ambien is currently being investigated across 1 indication[3], with its most advanced program in Phase 3.[1]
Ambien is one of 4 small molecule programs targeting Spine Fusion. It is currently in Phase 3.
1
Indications
20
Total Trials
2
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Spine Fusion
#DrugCompanyPhaseTrials
1Marcaine
IInnocoll
Approved
Rayos
RRoxane Laboratories
Approved
Ambien
SanofiPhase 3
Methadone Based ERAS
SSenthil Sadhasivam
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Insomnia10 trials
Show 7 more trials
Combined Behavioral/Pharmacological Therapy for Insomnia
Completed·—·Phase 2·NCT00044629·162 enrolled
ART2 trials
MACE2 trials
4 more indications
Driving1 trial
Prolonged Disorders of Consciousness1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zolpidem Tartrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]